Genstar Capital-backed Flourish Research completed the investment in Valkyrie Clinical Trials.

Genstar Capital-backed Flourish Research, a multi-site clinical trial organization focused primarily on cardiovascular, metabolic, neuroscience, and infectious disease therapeutic areas, completed the investment in Valkyrie Clinical Trials, a premier network of oncology-focused clinical research sites. Financial terms were not disclosed. "We are delighted to collaborate with Dr. Berz as we enter the oncology market. Valkyrie has achieved remarkable growth and provides deep medical and scientific expertise to an extensive client base, as well as comprehensive access to patients and referral networks. We look forward to continuing this growth story and realizing the vision of accelerating the development of innovative treatments and delivering lifesaving care to patients with unmet needs," Reinhold Schulz, Flourish CEO.